Synthesis and evaluation of 99mTc-analogues of [123/131I]mIBG prepared via [99mTc][Tc(CO)3(H2O)3]+ synthon for targeting norepinephrine transporter.

Abstract

INTRODUCTION:

meta-[123/131I]Iodobenzylguanidine (mIBG) is a clinical agent used for imaging neuroendocrine tumors, where uptake in tumor is via active transport mechanism through norepinephrine transporters (NET). Our group in past have evaluated a 99mTc-analogue of the above tracer, based on 99mTc-4 + 1 labeling approach, which exhibited significant affinity for NET but suffered from reduced specific uptake in comparison to reference standard no-carrier-added (n.c.a.) [125I]mIBG. The present work attempts to synthesize two new 99mTc-analogues of the radio-iodinated derivative following [99mTc]Tc(CO)31+ approach with an aim to improve the above specific uptake content.

METHODS:

Two different precursors, xylylenediamine and 1,3-bis(chloromethyl)benzene, were synthetically modified to yield meta-functionalized benzylguanidine derivatives bearing iminodiacetate (IDA) and aminoethylglycine (AEG) tridentate chelating moieties, respectively. These ligands were labeled with technetium-99m via [99mTc][Tc(CO)3(H2O)3]+ synthon to form desired radioactive complexes 9 and 10. The radiolabeling yields of the complexes obtained were >90% as confirmed by radio-HPLC. The HPLC purified complexes were used for in vitro and in vivo evaluation to understand the true biological efficacy. Structural characterization of the radiolabeled complexes was carried after synthesizing and characterizing their Re-analogues.

RESULTS:

Cell uptake studies with the radiolabeled complexes in SK-N-SH neuroblastoma cell lines revealed reduced uptake in the cells (<1% of incubated radioactivity/106 cells) in comparison to n.c.a. [125I]mIBG (~12%). However, limited specificity (~60%) was observed for the complexes as ascertained through desmethylimipramine (DMI) inhibition. Biodistribution studies in normal Wistar rats exhibited desired non-target clearance pharmacokinetics for the complexes but in vivo NET efficacy in myocardium for the neutral complex 10 could not be established.

CONCLUSIONS:

Tridentate [99mTc]Tc(CO)31+ chelation approach severely affects biological behavior of the present small bioactive molecule under study to a significant extent in comparison to monodentate ligation in 99mTc-4 + 1 strategy.

• Authors: Soumen Das, Navin Sakhare, Anupam Mathur, Madhava B Mallia, Shubhangi Mirapurkar, M Sheela, H D Sarma, S S Sachdev, Ashutosh Dash
• Journal: Nuclear medicine and biology (Nucl Med Biol) 2019 Jan - Feb Vol. 68-69 Pg. 49-57 ISSN: 1872-9614 [Electronic] United States
• PMID: 30770228 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Norepinephrine Plasma Membrane Transport Proteins
• 3-Iodobenzylguanidine
• Technetium

Topics

• 3-Iodobenzylguanidine (chemical synthesis, chemistry, metabolism, pharmacokinetics)
• Animals
• Cell Line, Tumor
• Chemistry Techniques, Synthetic
• Drug Stability
• Humans
• Norepinephrine Plasma Membrane Transport Proteins (metabolism)
• Radiochemistry
• Rats
• Rats, Wistar
• Technetium (chemistry)
• Tissue Distribution